Clinical Trial

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this trial is to learn if KQB548 works to treat patients with advanced solid malignancies with a KRAS G12D mutation. It will also learn about the safety of KQB548. The main questions it aims to answer are: * What is the safe dose of KQB548? * Does KQB548 decrease the size of the tumor? * What happens to KQB548 in the body?
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-10-02; most recent amendment 2026-05-18.
Trial Details
NCT Number NCT07207707
Lead Sponsor Kumquat Biosciences Inc.
Conditions Solid Tumor Malignancies
Enrollment 78 participants
Start Date 2025-09-16
Primary Completion 2026-09 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-20